metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus Ipilimumab (10 mg/kg)
	nivolumab alone
	CheckMate 238, 2017 N Engl J Med 2017;377:1824-1835 Journal of Dermatology 2019; 46:1197-. Lancet Oncol 2020 Sep 18;S1470-2045(20)30494-0. NCT02388906	RCT	mML - NA - all population	nivolumab	ipilimumab	patient, 15 years of age or older, with high-risk resected stage IIIB, IIIC, or IV melanoma as adjuvant treatment	453 / 453	low	conclusif	demonstrated 35 % decrease in RFS/DFS (PE) suggested 27 % decrease in MFS suggested 29 % decrease in RFS (extension)
versus placebo
	nivolumab alone
	IMMUNED (N vs P ; all population), 2020 Lancet 2020; 395:1558-1568 NCT02523313	RCT	mML - NA - all population	nivolumab	placebo	adjuvant therapy with nivolumab alone or in combination with ipilimumab compared with placebo in patients with stage IV melanoma with no evidence of disease	59 / 52	low	conclusif	demonstrated 44 % decrease in RFS/DFS (PE)
	pembrolizumab alone
	KEYNOTE 054 (all population), 2018 N. Engl. J. Med. 2018; 378:1789-1801 JAMA Oncol 2020; : European Journal of Cancer 2019; 116:148-. J Clin Oncol 2020 Sep 18;JCO2002110. J Med Econ 2019 Oct;22(10):981-993. JAMA Oncol 2020; 6:519-527 Lancet Oncol 2021 Apr 12;S1470-2045(21)00065-6. Lancet Oncol 2021 Apr 12;S1470-2045(21)00081-4. NEJM Evidence NCT02362594	RCT	mML - NA - all population	pembrolizumab	placebo	patients with complete Resection of High-Risk Stage III Melanoma, stage IIIA, IIIB or IIIC melanoma with no in-transit metastases,	514 / 505	low	conclusif	demonstrated 43 % decrease in RFS/DFS (PE) suggested 47 % decrease in MFS suggested 44 % decrease in RFS (extension) suggested 41 % decrease in RFS (extension) more...